RISK WATCHBenzinga • 2d ago
Allarity Therapeutics Terminates $6M Equity Purchase Agreement With Tumim Stone Capital To Pursue Alternative Financing; Says No Early Termination Penalty Is Payable-SEC Filing
Why ALLR Stock dropped -6.32% Today — RQD Quant Desk Flash
$0.89 -6.32% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
Allarity Therapeutics Inc. (ALLR) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $14.2M
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALLR)Realized 20D OHLCV Swing Band: ±12.5%
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ALLR Stock dropped -6.32% Today — RQD Quant Desk Flash
Allarity Therapeutics Inc. (ALLR) dropped -6.32% to $0.89, trading at 11% of its 52-week range ($0.77 – $1.84). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 11% of its 52-week range ($0.77 – $1.84) with RSI-14 at 38.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.89 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live ALLR Headlines & Catalysts
MARKET WIREYahoo • 2d ago
Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue- Agreement complements revenue from standard gene expression and DRP® services - Development and validation services will support a European biotechnology company’s precision oncology predictive device for use in the Un
CATALYSTBenzinga • 2d ago
Allarity Therapeutics Receives First Contract For Its Development, Validation And Related Laboratory Services From Undisclosed European Biotech FirmAllarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALLR)
- ✓Walkthrough of ALLR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ALLR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -34.07%▼ DESCENDING CHANNEL
2026-10-30O $0.89H $0.90L $0.85C $0.89VOL 178.6K
RES: $1.28SUP: $0.76SMA50: $1.10SMA200: $1.22
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ALLR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ALLR today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ALLR. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ALLR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALLR)
Health Care Rank #728 of 1016
⚔️ BFRI vs ALLR Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ALLR vs. BFRI, OPTH, DARE, CTXR)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Allarity Therapeutics Inc. (ALLR) ranks #728 by composite RQD confidence (38/100, grade D-) and #861 by equity capitalization ($14.2M). Within this direct 5-issuer industry benchmark cohort, ALLR leads on earnings valuation at N/A trailing P/E, while ALLR leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. OPTH currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with ALLR at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ALLR
ACTIVE
Allarity Therapeutics Inc. | D- | 38/100 | — | — | -35.0% | -6.32% | $14.2M | Benchmark Subject |
| BFRI Biofrontera Inc. | D- | 40/100 | — | — | -35.0% | +5.09% | $13.8M | /bfri-vs-allr → |
| OPTH Optimi Health Corp. | D | 49/100 | — | — | — | -6.81% | $14.9M | /opth-vs-allr → |
| DARE Dare Bioscience Inc. | D | 44/100 | — | 71.3% | -35.0% | +0.22% | $13.4M | /dare-vs-allr → |
| CTXR Citius Pharmaceuticals Inc. | D | 49/100 | — | — | -35.0% | +4.07% | $15.5M | /ctxr-vs-allr → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001860657In its most recent audited fiscal period (FY2025, filed 2025-12-31), Allarity Therapeutics Inc. (ALLR) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$11.2M, operating cash flow of -$14.8M, and free cash flow of -$14.8M (+16.0% YoY). On the balance sheet, ALLR closed FY2025 with $18.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$11.2M | -$14.8M | -$14.8M | $18.3M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$24.5M | -$17.4M | -$17.6M | $22.6M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$11.9M | -$12.7M | -$12.7M | — | — |
3. ALLR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ALLR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Allarity Therapeutics Inc. (NASDAQ: ALLR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.89 (-6.32% 1D, market cap $14.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ALLR ranks #728 in composite RQD confidence.
How does ALLR compare to BFRI and OPTH in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALLR carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BFRI (Biofrontera Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $13.8M) and OPTH (Optimi Health Corp.) posts a D grade (49/100 RQD, P/E N/A, ROIC —, cap $14.9M). Among the 5-stock peer group, ALLR leads on earnings multiple (N/A) while ALLR leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ALLR?
Per ALLR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001860657), Allarity Therapeutics Inc. generated $0 in revenue, -$11.2M in net income, and -$14.8M in free cash flow against $18.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ALLR trading relative to its 50-day, 200-day, and 52-week technical levels?
ALLR last traded at $0.89 (-6.32% on volume of 150,076 shares), positioning the stock -19.09% below its 50-day simple moving average ($1.10) and -27.05% below its 200-day simple moving average ($1.22). Across its 52-week range of $0.77 to $1.84, ALLR sits at the 11.2% percentile with a 14-day RSI of 38.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.00).
ALLR Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ALLR stock moving today?
Why ALLR Stock dropped -6.32% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.